title: Neuroleptic malignant syndrome without neuroleptics.
authors.forename: M A
authors.initials: MA
authors.lastname: Parsa
authors.forename: T
authors.initials: T
authors.lastname: Rohr
authors.forename: L F
authors.initials: LF
authors.lastname: Ramirez
authors.forename: H Y
authors.initials: HY
authors.lastname: Meltzer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents; D002230:Carbidopa / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D010300:Parkinson Disease / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D014191:Tranylcypromine / Q000009:adverse effects* / Q000627:therapeutic use; D014364:Tryptophan / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000978:Antiparkinson Agents; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D014191:Tranylcypromine; D007980:Levodopa; D014364:Tryptophan; D002230:Carbidopa